Investors May Lead Class Action Lawsuit Against Regeneron
Investors who have suffered substantial losses in Regeneron Pharmaceuticals (NASDAQ: REGN) are being notified of a securities class action lawsuit. The action follows the company's revelations regarding a Phase 3 clinical trial.
A securities class action lawsuit has been filed against Regeneron Pharmaceuticals (NASDAQ: REGN), offering an opportunity for investors who have experienced significant financial losses. The suit stems from recent revelations by the company concerning a Phase 3 clinical trial for a therapy.
Law firm Hagens Berman Sobol Shapiro LLP is alerting investors eligible to serve as lead plaintiff. The lawsuit alleges that Regeneron and certain of its officers and directors made materially false or misleading statements to investors regarding the company's business and prospects.
The core of the complaint appears to be related to the unexpected outcome of a critical clinical trial. The specific details of the trial and the alleged misrepresentations are central to the legal proceedings. Investors who wish to participate are advised to contact the law firm for more information and to meet the filing deadlines.